Loading...
•
Mar 31, 2020
Regeneron Q1 2020 Earnings Report
Regeneron's Q1 2020 financial results were announced, highlighting revenue growth and key pipeline advancements.
Key Takeaways
Regeneron reported a strong first quarter in 2020, with revenues increasing by 33% to $1.83 billion. The company saw growth in key products like EYLEA, Dupixent, and Libtayo, and is advancing its COVID-19 antibody cocktail treatment.
First quarter revenues increased by 33% to $1.83 billion compared to Q1 2019.
GAAP diluted EPS was $5.43 and non-GAAP diluted EPS was $6.60 for the first quarter.
EYLEA U.S. net sales increased by 9% to $1.17 billion in the first quarter compared to the previous year.
Dupixent global net sales, recorded by Sanofi, increased by 129% to $855 million versus first quarter 2019.
Revenue by Segment
Forward Guidance
Regeneron provided full year 2020 financial guidance, including GAAP and non-GAAP estimates for R&D, SG&A, COGS, COCM, other operating income/expense, capital expenditures, and effective tax rate.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...